Aleman, Julio https://orcid.org/0000-0001-7530-3303
K, Ravikumar
Wiegand, Connor
Schurdak, Mark E.
Vernetti, Lawrence https://orcid.org/0000-0003-4861-3167
Gavlock, Dillon
Reese, Celeste
DeBiasio, Richard
LaRocca, Greg
Angarita, Yulder Daniel
Gough, Albert https://orcid.org/0000-0001-6456-0195
Soto-Gutierrez, Alejandro
Behari, Jaideep
Yechoor, Vijay K. https://orcid.org/0000-0002-9981-6784
Miedel, Mark T. https://orcid.org/0000-0002-0132-6032
Stern, Andrew M.
Banerjee, Ipsita
Taylor, D. Lansing https://orcid.org/0000-0001-6947-1343
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UH3TR003289, U24TR002632, U24TR002632, U24TR002632)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (UH3DK119973, R01DK117881, R01DK135606, UH3DK119973)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (S10OD028450)
NSF | ENG/OAD | Division of Chemical, Bioengineering, Environmental, and Transport Systems (1706674, 2229156)
Article History
Received: 8 May 2024
Accepted: 2 October 2024
First Online: 14 October 2024
Competing interests
: D.L.T., A.G., and M.E.S. have equity in Nortis, a company supplying MPS chips/some automation and EveAnalytics (accessing, analyzing, and computationally modeling data on patient-derived microphysiology systems).